Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

19    Otsuka    $5.2B    up 13.0%
Global revenue*: $13.1B (16th); down 2.2% 

R&D spend*: $2.0B (15th), up 11.7%; 14.5% of rev.

Top brands: Abilify ($5.2B), Samsca ($48M), Busulfex ($12M), Pletal ($2M)

Planned launches: Sativex (pain)

Promotional spend: $15M (19th); 0.3% of rev.

Patent expirations: Abilify (2015)

The Japanese holding company remains dependent upon its blockbuster antipsychotic drug Abilify, which it co-promotes with Bristol-Myers Squibb. In the fiscal year ending March 31, 2011, the drug provided half of the company's income. Otsuka says its goal is to continue to focus on teaming up with companies for research, with an emphasis on CNS and oncology. The company also noted that the earthquake that rocked Japan and toppled several warehouses did not significantly affect business.
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 19 of 21
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"